{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:02:59Z","timestamp":1773871379225,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04812-8","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T19:42:34Z","timestamp":1758656554000},"page":"1269-1276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term clinical efficacy and cognitive impact of medications for overactive bladder related to the central nervous system"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-9868","authenticated-orcid":false,"given":"Yu Khun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"1","key":"4812_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37\u201349. https:\/\/doi.org\/10.1016\/s0090-4295(02)02243-4","journal-title":"Urology"},{"key":"4812_CR2","first-page":"33","volume":"110","author":"B Haylen","year":"2012","unstructured":"Haylen B, De Ridder D, Freeman R, Swift S, Berghmans B, Lee J, Monga A, Petri E, Rizk D, Sand P (2012) An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. J Assoc Charter Physiother Womens Health 110:33","journal-title":"J Assoc Charter Physiother Womens Health"},{"issue":"2","key":"4812_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/ncpuro0021","volume":"1","author":"K-E Andersson","year":"2004","unstructured":"Andersson K-E (2004) Mechanisms of disease: central nervous system involvement in overactive bladder syndrome. Nat Clin Pract Urol 1(2):103\u2013108. https:\/\/doi.org\/10.1038\/ncpuro0021","journal-title":"Nat Clin Pract Urol"},{"issue":"Suppl 8","key":"4812_CR4","first-page":"S3","volume":"5","author":"N Yoshimura","year":"2003","unstructured":"Yoshimura N, Chancellor MB (2003) Neurophysiology of lower urinary tract function and dysfunction. Rev Urol 5(Suppl 8):S3\u2013S10","journal-title":"Rev Urol"},{"issue":"1","key":"4812_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/nau.24806","volume":"41","author":"CH Chiang","year":"2022","unstructured":"Chiang CH, Chen SF, Kuo HC (2022) Video-urodynamic characteristics of lower urinary tract dysfunctions in patients with chronic brain disorders. Neurourol Urodyn 41(1):255\u2013263. https:\/\/doi.org\/10.1002\/nau.24806","journal-title":"Neurourol Urodyn"},{"issue":"23","key":"4812_CR6","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2165\/00003495-200363230-00003","volume":"63","author":"KE Andersson","year":"2003","unstructured":"Andersson KE, Pehrson R (2003) CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 63(23):2595\u20132611. https:\/\/doi.org\/10.2165\/00003495-200363230-00003","journal-title":"Drugs"},{"issue":"3","key":"4812_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543\u2013562","journal-title":"Eur Urol"},{"issue":"2","key":"4812_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016718","volume":"6","author":"TM Kessler","year":"2011","unstructured":"Kessler TM, Bachmann LM, Minder C, L\u00f6hrer D, Umbehr M, Sch\u00fcnemann HJ, Kessels AG (2011) Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 6(2):e16718. https:\/\/doi.org\/10.1371\/journal.pone.0016718","journal-title":"PLoS One"},{"issue":"11","key":"4812_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F (2018) Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open 8(11):e021889. https:\/\/doi.org\/10.1136\/bmjopen-2018-021889","journal-title":"BMJ Open"},{"issue":"1","key":"4812_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E (2020) Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol 77(1):119\u2013128. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.024","journal-title":"Eur Urol"},{"issue":"1","key":"4812_CR11","doi-asserted-by":"publisher","first-page":"11355","DOI":"10.1038\/s41598-020-68170-4","volume":"10","author":"C-K Huang","year":"2020","unstructured":"Huang C-K, Lin C-C, Lin AT-L (2020) Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep 10(1):11355. https:\/\/doi.org\/10.1038\/s41598-020-68170-4","journal-title":"Sci Rep"},{"issue":"7","key":"4812_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/nau.22645","volume":"34","author":"HC Kuo","year":"2015","unstructured":"Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2015) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn 34(7):685\u2013692. https:\/\/doi.org\/10.1002\/nau.22645","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"4812_CR13","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/ggi.13465","volume":"18","author":"YK Lee","year":"2018","unstructured":"Lee YK, Kuo H-C (2018) Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int 18(9):1330\u20131333. https:\/\/doi.org\/10.1111\/ggi.13465","journal-title":"Geriatr Gerontol Int"},{"issue":"1","key":"4812_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12894-022-00989-7","volume":"22","author":"H Nakagomi","year":"2022","unstructured":"Nakagomi H, Mitsui T, Shimura H, Ihara T, Kira S, Sawada N, Takeda M (2022) Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol 22(1):40. https:\/\/doi.org\/10.1186\/s12894-022-00989-7","journal-title":"BMC Urol"},{"issue":"1","key":"4812_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/nau.24549","volume":"40","author":"W Gibson","year":"2021","unstructured":"Gibson W, Johnson T, Kirschner-Hermanns R, Kuchel G, Markland A, Orme S, Ostaszkiewicz J, Szonyi G, Wyman J, Wagg A (2021) Incontinence in frail elderly persons: report of the 6th International Consultation on Incontinence. Neurourol Urodyn 40(1):38\u201354. https:\/\/doi.org\/10.1002\/nau.24549","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"4812_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","volume":"67","author":"P Abrams","year":"2015","unstructured":"Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67(3):577\u2013588. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.012","journal-title":"Eur Urol"},{"issue":"1","key":"4812_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","volume":"70","author":"MJ Drake","year":"2016","unstructured":"Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, St\u00f6lzel M, Herholdt C, MacDiarmid S (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70(1):136\u2013145. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.030","journal-title":"Eur Urol"},{"issue":"6","key":"4812_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2019.07.010","volume":"76","author":"C Gratzke","year":"2019","unstructured":"Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E (2019) Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment. Eur Urol 76(6):767\u2013779. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.010","journal-title":"Eur Urol"},{"issue":"4","key":"4812_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","volume":"74","author":"C Gratzke","year":"2018","unstructured":"Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER (2018) Long-term safety and efficacy of Mirabegron and Solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol 74(4):501\u2013509. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.005","journal-title":"Eur Urol"},{"issue":"10","key":"4812_CR20","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jfma.2022.04.004","volume":"121","author":"S-F Chen","year":"2022","unstructured":"Chen S-F, Chuang Y-C, Wang C-C, Liao C-H, Kuo H-C (2022) Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system disorders\u2014a cohort study. J Formos Med Assoc 121(10):2101\u20132108. https:\/\/doi.org\/10.1016\/j.jfma.2022.04.004","journal-title":"J Formos Med Assoc"},{"issue":"Supp. 1","key":"4812_CR21","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.5152\/tud.2020.20092","volume":"46","author":"M Moussa","year":"2020","unstructured":"Moussa M, Papatsoris A, Chakra MA, Fares Y, Dellis A (2020) Lower urinary tract dysfunction in common neurological diseases. Turk J Urol 46(Supp. 1):S70-s78. https:\/\/doi.org\/10.5152\/tud.2020.20092","journal-title":"Turk J Urol"},{"issue":"6","key":"4812_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ (2016) Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 73(6):721\u2013732. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0580","journal-title":"JAMA Neurol"},{"issue":"8","key":"4812_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5498\/wjp.v11.i8.412","volume":"11","author":"DM Conde","year":"2021","unstructured":"Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L (2021) Menopause and cognitive impairment: a narrative review of current knowledge. World J Psychiatry 11(8):412\u2013428. https:\/\/doi.org\/10.5498\/wjp.v11.i8.412","journal-title":"World J Psychiatry"},{"issue":"2","key":"4812_CR24","doi-asserted-by":"publisher","first-page":"e210169","DOI":"10.1001\/jamanetworkopen.2021.0169","volume":"4","author":"DA Levine","year":"2021","unstructured":"Levine DA, Gross AL, Brice\u00f1o EM, Tilton N, Giordani BJ, Sussman JB, Hayward RA, Burke JF, Hingtgen S, Elkind MSV, Manly JJ, Gottesman RF, Gaskin DJ, Sidney S, Sacco RL, Tom SE, Wright CB, Yaffe K, Galecki AT (2021) Sex differences in cognitive decline among US adults. JAMA Netw Open 4(2):e210169\u2013e210169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0169","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4812_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","volume":"64","author":"A Wagg","year":"2013","unstructured":"Wagg A, Dale M, Tretter R, Stow B, Compion G (2013) Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 64(1):74\u201381. https:\/\/doi.org\/10.1016\/j.eururo.2013.01.002","journal-title":"Eur Urol"},{"issue":"11","key":"4812_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","volume":"18","author":"B Welk","year":"2021","unstructured":"Welk B, Richardson K, Panicker JN (2021) The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol 18(11):686\u2013700. https:\/\/doi.org\/10.1038\/s41585-021-00504-x","journal-title":"Nat Rev Urol"},{"issue":"12","key":"4812_CR27","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/jgs.12541","volume":"61","author":"B Lam","year":"2013","unstructured":"Lam B, Middleton LE, Masellis M, Stuss DT, Harry RD, Kiss A, Black SE (2013) Criterion and convergent validity of the Montreal cognitive assessment with screening and standardized neuropsychological testing. J Am Geriatr Soc 61(12):2181\u20132185. https:\/\/doi.org\/10.1111\/jgs.12541","journal-title":"J Am Geriatr Soc"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04812-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04812-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04812-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:37:36Z","timestamp":1773844656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04812-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4812"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04812-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}